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Abstract
The induction of a strong mucosal immune response is essential to building successful HIV vaccines. Highly attenuated
recombinant HIV vaccinia virus can be administered mucosally, but even high doses of immunization have been found
unable to induce strong mucosal antibody responses. In order to solve this problem, we studied the interactions of
recombinant HIV vaccinia virus Tiantan strain (rVTT-gagpol) in mucosal epithelial cells (specifically Caco-2 cell layers) and in
BALB/c mice. We evaluated the impact of this virus on HIV antigen delivery and specific immune responses. The results
demonstrated that rVTT-gagpol was able to infect Caco-2 cell layers and both the nasal and lung epithelia in BALB/c mice.
The progeny viruses and expressed p24 were released mainly from apical surfaces. In BALB/c mice, the infection was limited
to the respiratory system and was not observed in the blood. This showed that polarized distribution limited antigen
delivery into the whole body and thus limited immune response. To see if this could be improved upon, we stimulated
unpolarized budding of the virus and HIV antigens by treating both Caco-2 cells and BALB/c mice with colchicine. We found
that, in BALB/c mice, the degree of infection and antigen expression in the epithelia went up. As a result, specific immune
responses increased correspondingly. Together, these data suggest that polarized budding limits antigen delivery and
immune responses, but unpolarized distribution can increase antigen expression and delivery and thus enhance specific
immune responses. This conclusion can be used to optimize mucosal HIV vaccine strategies.
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Introduction
AIDS (acquired immune deficiency syndrome) remains the
great unconquered threat to global public health. An effective HIV
vaccine is urgently needed. Ninety percent of AIDS cases are
transmitted through mucosal routes, such as sexual contact [1].
Targeting immune responses to the site of viral entry can protect
the body and help clear the viral reservoir before HIV
dissemination [2,3]. There is evidence that HIV-specific S-IgA
could neutralize HIV in the cervicovaginal lavage fluids of
uninfected partners of highly exposed persons [4,5,6,7,8]. The
SIV-specific CTLs, which are induced by immunization with an
attenuated SHIV, were found to be associated with protection
against vaginal challenge in rhesus macaques [9]. Most researchers
believe that a vaccine against HIV-1 would need to induce a
neutralizing antibody, CD4
+ Th, and competent CD8
+ CTL
responses at the initial site of viral entry. Systemic vaccination is
not sufficient to generate effective compartmentalized mucosal
immunity [2,10].
However, inducing robust mucosal immune responses is
difficult. Several factors contribute to successful mucosal immunity
[11,12,13]. The key factors are as follows: (i) effective delivery of
the antigen to the mucosal immune induction site; (ii) enhance-
ment of the mucosal immune responses via safe mucosal
adjuvants; (iii) regimen and route of immunization that induce
protective responses at the desired mucosal site, preferably
systemically; and (iv) adequate vaccine formulation [14].
The vaccinia virus (VV) has been used as a smallpox vaccine. It
helped eradicate smallpox worldwide. As a live vaccine vector, it
was used for the prevention and eradication of many infectious
diseases due to its broad host range, large foreign DNA capacity,
lack of carcinogenicity, and ability to induce the expression of
foreign antigens in eukaryotic cells [15,16,17]. The recombinant
wild vaccinia virus is generally avoided for safety reasons,
particularly with regard to young children and immune-compro-
mised individuals [18,19]. As a result, in China, Chen and his
colleges developed a series of highly attenuated vaccinia virus
Tiantan strains by decreasing the neurotoxicity of the virus
[20,21,22]. Preliminary experiments demonstrated that the highly
attenuated vaccinia virus could induce both humoral and cell-
mediated immune responses [20]. One intranasal immunization of
this virus protected animals from challenge with the pathogenic
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Control and Prevention (China) developed an AIDS vaccine
candidate using DNA priming and rVV Tiantan boost with env
and gag-pol of CRF07_B’/C as inserts. It has been approved by
the SFDA for a phase I trials. Volunteer recruitment started in
Beijing in November of 2007 [23,24].
Unfortunately, highly attenuated recombinant vaccinia viruses
can induce only limited mucosal immune responses specific to
foreign antigens, even at high doses. Enhancing these immune
responses or reducing the necessary dose, would render the
vaccine easier to make and safer for patients. Regarding obstacles
to mucosal immunization, the first line of opposition that a vaccine
encounters is the long-lined mucosal epithelium. There have been
some reports that measles and Junin viruses infect the polarized
epithelium and are released in a polarized way [25,26,27]. We
performed this study to evaluate interactions between recombinant
vaccinia viruses and epithelial cells and to determine whether
epithelial cells released HIV antigens in a polarized way. Upon
finding that they did, we performed more tests to see what
influence this polarized release has on antigen delivery and specific
immune responses. Here we report that recombinant HIV
vaccinia virus can infect the mucosal epithelium in vitro and in
BALB/c mice; both the progeny vaccinia virus and HIV antigen
are preferentially released from the apical surfaces and colchicine
treatment causes unpolarized antigen expression, delivery, and
enhanced specific immune responses. These results provide
guidance for immune enhancement and dose reduction in HIV
vaccination.
Materials and Methods
Cell lines
Caco-2 human colonic carcinoma cell line and Vero cell line
were obtained from American Type Culture Collection (Rockville,
MD, U.S.). Caco-2 cells were maintained in DMEM (Gibco)
supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco),
12.6 mM HEPES, 100 U/ml penicillin, 100 mg/ml streptomycin
(Gibco, 1% P+S), and 16nonessential amino acids (MEM-NEAA,
10 mM, 100X, Gibco). Vero cells were maintained in an
otherwise identical DMEM medium containing NEAA. Both
were incubated at 37uC in a humidified atmosphere of 5% CO2.
Mice
Female BALB/c mice, 6–8 weeks old, were purchased from the
Hunan SJA Laboratory Animal Co., Ltd. and maintained in the
Animal Center (Wuhan Institute of Virology, Chinese Academy of
Sciences) under specific pathogen-free (SPF) conditions. Female
mice were chosen because previous studies have suggested that
nasal priming does not work well in male mice [28]. All
experiments were approved by the Wuhan Institute of Virology
Experimental Animal Ethics and Welfare Committee, the permit
number is A2008-019.
Viral preparation
rVTT-gagpol vaccinia virus was provided by Dr. Zhi-wei Chen
(Director of HKU-AIDS Institute) and constructed by Dr. Ke
Zhuang (College of Life Sciences, Wuhan University). The virus
was homologously recombined with the gagpol gene from HIV-1
B9 and a gfp gene to replace most of the vaccinia virus HA gene. It
was propagated in Vero cells. Cells were frozen and thawed three
times and centrifuged at 2000 rpm for 20 minutes. Supernatants
were aspirated, aliquoted, and stored at 270uC.
Viruses were purified and enriched for immunization. Large-
scale propagation of viruses from Vero cells and the supernatant of
frozen and thawed cells was added to the 36% (m/v) sucrose
solution and centrifuged at 18,000 g for 80 minutes at 4uC. The
deposits were suspended, aliquoted at about 1610
9 PFU/ml in
PBS, and stored at 270uC.
The viral titer was determined by plaque assay of Vero cells.
Immunization
Mice were primed and boosted with 10
7 PFU/mouse of rVTT-
gagpol (12 ml) at 0 and 4 weeks and euthanized at week 6 (Fig. 1A).
For tests of viral and antigen distribution, mice in the colchicine
group were i.n. inoculated with colchicine (Duchefa, 20 mg/
mouse, 1.25 mg/ml, 16 ml) 72 hours before rVTT-gagpol
(10
7 PFU/mouse, 12 ml) immunization. In the control group,
PBS replaced colchicine (Fig. 1B).
Regarding specific antibody response tests, mice in the
colchicine group were i.n. primed by rVTT-gagpol (10
7 PFU/
mouse, 12 ml) and colchicine (40 mg/mouse, 10 mg/ml, 4 ml) and
then i.n. boosted with colchicine (4 mg/mouse, 1 mg/ml, 4 ml)
24 hours before immunization with rVTT-gagpol (10
7 PFU/
mouse, 12 ml) at week 4. They were euthanized at week 6 (Fig. 1C).
I.n. immunization was performed under anesthesia by 0.06–
0.07 mg/g pentobarbital. There were 4–7 mice in each group.
Collection of serum and mucosal samples
Before euthanasia, vaginal washes were collected. Forty
microliters of PBS was aspirated into the vaginal tract using
200-ml tips. The fluid was blown and aspirated 10 times and
washed twice. Then serum was obtained. For collection of lung
bronchial washes (BW), the trachea was exposed surgically and
breast diaphragm was opened for subsequent lung expansion. A
very small cut was made on the trachea with small surgical scissors.
A 1-ml tip covered with a 10-ml tip from a 1-ml pipette was used to
aspirate 500-ml PBS with 1% BSA. The apparatus was carefully
inserted into the trachea with the tip toward to lung. This was
blown and aspirated three times, slowly, to completely wash the
whole lung and bronchia. Both vaginal washes and BW were
centrifuged at 2000 rpm for 10 minutes before being stored at
270uC.
Kinetics of antigen distribution in vivo
Mice were immunized and euthanized 1, 12, 24, 48, 72, or
96 hours later. The collecting method was similar to that used
previously [29]. Heparinized (20 U/ml) blood was collected and
centrifuged at 2000 rpm. Nasal washes and lung bronchial washes
were collected in 1 ml DMEM with 1% (P+S) and 10% FBS. The
method of collecting bronchial washes is described as above. For
nasal washes, the initial steps were the same as those used for
bronchial washes, but after the small cut was made on the trachea,
a 1-ml tip covered with a 10-ml tip from a 1-ml pipette was
carefully inserted into trachea with the tip toward the nostril, and
solution was to made to flow out of nostrils. It was washed twice.
The nasal turbinate and lungs were separately homogenized in
1 ml DMEM with 1% (P+S) and 10% FBS. Washes and
homogenized samples were centrifuged at 2000 rpm for 10
minutes. The vaccinia viral titer and p24 concentration were
determined by plaque assay and ELISA, respectively.
Immunohistochemical staining of p24 in mice
After immunization, mice were bled and euthanized. The nasal
turbinate and lungs were collected and fixed in 10% (v/v)
formaldehyde for 6–12 hours. The decalcification of nasal
turbinate was performed in cooled 5% (v/v) nitric acid in a
microwave oven [30]. Decalcification solution was maintained at
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every 5–10 minutes for 1 hour. Then both the lung and the
decalcified nasal turbinate samples underwent serial dehydration
and were imbedded in paraffin and cut into slices 2 mm thick.
The tissue sections were heated, rehydrated, and subjected to
antigen retrieval procedures, including microwaving in 0.01 M
citrate buffer (pH 6.0) and incubation in 3% hydrogen peroxide in
deionized water. The following experiment was performed using
ZSGB-BIO, sp-9001 Histostrain
TM-Plus Kits: After tissue sections
were blocked for 30 minutes at room temperature, they were
incubated with rabbit anti-p24 (1:3000, gift of Dr. Bing Yan,
Wuhan Institute of Virology, Chinese Academy of Sciences) for
2 hours at 37uC. Then the tissue sections were incubated with
biotin-labeled goat anti-rabbit antibody and strep-HRP separately
for 15 minutes at room temperature. They were then visualized
using diaminobenzidine (DAB) kit (Maixin-Bio). Before primary
antibody incubation, the samples were washed three times with
PBS. After primary antibody incubation, they were washed three
times with PBS with 0.02% (v/v) Tween 20 and twice with PBS
alone. All slides were counterstained with hematoxylin solution.
Slides were photographed in an OLYMPUS BX51 microscope
equipped with QImaging CCD camera (MiroPublisher 5.0 RTV)
and QCapture vision software.
Plaque assay
The experiment was performed under a biosafety hood using
aseptic technique. Vero cells were seeded in 24-well plates and
incubated for 24 hours. Serial 10-fold dilutions were inoculated for
2 hours. Inocula were removed and washed with 0.5 ml PBS.
Then freshly prepared 1% (m/v) agarose and 26MEM (Gibco,
6% FBS+1% (P+S)) were added. Each plate was incubated for
48 hours, and 0.2 ml of 5 mg/ml crystal violet in 10%
formaldehyde was added to fix and stain the cell layers for
2 hours at room temperature. Then the agarose was carefully
flushed out with tap water and the plates were air-dried. Plaques
were counted. PFU (plaque formation unit)=dilution6P6(1/V),
(P: plaque counts; V: volume of inocula).
ELISA (anti-p24 antibody and p24 antigen detection)
For anti-p24 antibody detection, 5 mg/ml E. coli recombinant
p24 protein was coated in 0.1 M carbonate bicarbonate buffer
(pH 9.6) at 37uC for 2.5 hours. Then plates were blocked with 1%
BSA in PBS at 4uC overnight. Serial 4-fold dilutions of sample in
PBS (0.5% BSA) were added to the plates and incubated for
2 hours at 37uC. Then goat anti-mouse IgG-AP (1:2000, Southern
Biotech) or goat anti-mouse IgA-AP (1:2000, Southern Biotech ) in
PBS (0.5% BSA) was added and incubated for 1 hour at 37uC.
The colorimetric conversion was performed using Sigma Fast
TM,
p-nitrophenylphosphate (PNPP) tablet sets (Sigma, N-2770) for
1 hour at 37uC. After each incubation (but not after blocking),
plates were washed with 0.05% Tween 20 in PBS. Plates were
evaluated in a microplate spectrophotometer (Multiskan MK3,
Thermo LabSystems) at 405 nm and the readouts were calibrated
with blanks. Titers of the samples were calculated from endpoint
dilutions twice the negative value.
For p24 protein detection, the double antibody sandwich
method was used. Diluted rabbit anti-p24 poly-antibody (1:500)
was coated in 0.1 M carbonate bicarbonate buffer (pH 9.6) at
37uC for 2.5 hours. Then plates were blocked using 10% FBS in
PBS at 4uC overnight. Plates containing treated samples were
serially 2-fold or 4-fold diluted with PBS containing 10% FBS
and 1% (v/v) TritonX-100 and treated for 3 hours at 37uCt o
release p24 from the HIV-virus-like particle. E. coli recombinant
p24 diluted in the same manner was used to create a standard
curve to determine the concentration of p24 in samples. Then
treated and untreated sample dilutions were placed in wells for
Figure 1. Immunization schemes. (A) I.n. immunization. (B) Colchicine i.n. immunization for distribution of virus and antigen. (C) Colchicine i.n.
immunization for antibody tests.
doi:10.1371/journal.pone.0024296.g001
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added and incubated for 1 hour at 37uC. The colorimetric
conversion of TMB substrate reagent was used for 10–20 minutes
at room temperature. The working solutions were as follows:
250 ml solution B +10 ml buffer A +3.75 ml 30% H2O2. Buffer A:
205 mM potassium citrate (pH 4.0). Solution B: 41 mM TMB in
DMSO [31]. After each incubation, but not after blocking, plates
were washed with 0.05% Tween 20 in PBS. Colorimetric
conversions of the substrate were read at 450 nm and 570 nm.
OD value = (OD value at 450 nm) 2 (OD value at 570 nm).
The p24 standard curve was drawn and a linear regression
equation was made. The linear range was 0.005 ng/ml to
0.1 ng/ml. The p24 concentration of the sample was computed
using the equation.
Polarized Caco-2 monolayers
Monolayers were grown in 12-well Corning Costar Transwell
plates (Corning Inc., U.S.) with 0.4-mmo r3 - mm pore filter inserts.
Cells were cultured for 14–16 days after becoming confluent
(which took about 2 days). The medium was changed every other
day so that would be well polarized. The TER readings were
about 600 Ohm/cm
2 (as measured by a Millicell-ERS voltmeter;
Millipore Corp., U.S.).
rVTT-gagpol infection of Caco-2 cells
Polarized Caco-2 monolayer cells were infected with rVTT-
gagpol apically at MOI (multiplicity of infection) 1. Virus was
added directly onto the apical surface and incubated at 37uCi n
3% FBS-containing DMEM medium. The same medium was
added to the basolateral compartment. Virus was aspirated after
2 hours. The apical surface was washed three times with PBS.
Then the cultures were fed fresh medium and returned to the
incubator. Infected polarized Caco-2 monolayer cells were
sampled at 0, 24, 48, and 72 hours post-infection. Apical,
basolateral media were collected. Cells were frozen and thawed
three times. Finally, three types of samples from apical media,
basolateral media, and cells were aliquoted and stored at 270uC.
In the unpolarized group, starter cells were seeded in transwells
for 3 days and then infected with rVTT-gagpol. In the colchicine-
treated group, colchicine (0.08 mg/ml) was added to polarized
Caco-2 cell layers 72 hours before infection. Forty-eight hours
after infection, apical and basolateral media were collected and
fresh medium was added. All samples were collected at 72 hours.
The p24 and viral titer were determined by ELISA and plaque
assay, respectively. The virus titer this time was calculated as the
sum of that collected at 48 hours and at 72 hours. Experiments
were performed double or in triplicate.
Electron microscopy
Each monolayer was rinsed with PBS and fixed with 2%
formaldehyde and 0.1% glutaraldehyde in 0.1 M sodium
phosphate buffer, pH 7.2, at 4uC for 2–4 hours [32]. Following
fixation, the cells on filters were cut free of the plastic inserts,
postfixed in OsO4, contrasted en bloc with 1% uranyl acetate,
dehydrated in a graded series of ethanol solutions, and embedded
in epon. Sections were cut perpendicularly to the filter, collected
on Formvar-coated mesh grids, and examined under a JEM-1230
electron microscope.
Statistical analyses
All statistical analyses were conducted using GraphPad Prism,
version 4. Statistical comparisons were conducted using the 2-
tailed unpaired t test. P values ,0.05 were considered significant.
Results
Effects of high doses of rVTT-gagpol on levels of mucosal
humoral immune response after intra-nasal
immunization
To evaluate the mucosal immune responses associated with
rVTT-gagpol, BALB/c mice were intra-nasally administered 10
7
PFU of rVTT-gagpol (Fig. 2). During week 6, after two
immunizationsfourweeksapart,micewereeuthanizedandantibody
levels were determined. In detail, the anti-p24 serum IgG titer was
about7500,theserumIgAtiterwasabout20,thelungwashIgAtiter
was about 18, the vaginal wash IgA titer was about 7, and no
significant differences from the PBS group were found (Fig. 2). The
anti-p24 IgG titer in lung washes was found to be higher than that of
IgA (data not shown). However, IgG levels were not stable at the
mucosal surface [33]. Vaginal washes were not evaluated for IgG.
This showed that high-dose rVTT-gagpol immunization could
induce high levels of p24-specific IgG in serum but only low IgA
titers, suggesting a weak mucosal immune response.
These results were similar to those reported by other groups: In
one study, 5610
6 PFU/mouse of recombinant vaccinia virus was
given to mice at 0 and 4 weeks, and these mice were then
euthanized and sampled at 6 weeks [34]. The specific IgA in lung
washes was shown via OD values and could be converted to about
20 titer. Another group gave its mice 2610
6 PFU i.n. only once
and euthanized them 3 weeks later. Their specific antibody results
were as follows: serum IgG 2 10061,370, serum IgA 8.064.2,
bronchial wash IgA 24.0626.3 [29].
Although rVTT-gagpol is a replicating virus vaccine, it still
needs high doses to induce even small mucosal immune responses
after mucosal immunization. In order to find the reasons behind
this and ways to enhance immune response and reduce the dose,
we studied the interactions between rVTT-gagpol and polarized
epithelia.
Release of rVTT-gagpol and HIV antigen p24 from
epithelial cells in vitro
It is known that epithelial cell layers are polarized in vivo. In vitro,
mucosal epithelial cell lines cultured on a permeable membrane
called a transwell can become polarized monolayers. In this study,
the human colonic carcinoma Caco-2 cell line was cultured and
developed into polarized cell layers. rVTT-gagpol was inoculated
from the apical side. Then small, local cytopathic effects (CPEs)
appeared in the cell layer: Some loose connections were formed
between neighboring cells but these had no great effect on the
integrity of the monolayer. The infected cell monolayer was fixed
and processed for electronic microscopy. p24 concentrations and
rVTT viral titers in the apical, basolateral, and cell samples were
determined at various time points.
The polarized cell monolayer was observed under electronic
microscopy (Fig. 3A). Some viral factories were present in the cell
plasma, in which there were many round immature vaccinia
viruses of about 200 nm in diameter (Fig. 3B). Some of the gagpol
assembled HIV-virus-like particles (VLP), about 100 nm in
diameter, were in the process of being transported (Fig. 3C) and
some were outside of the cells’ apical surface (Fig. 3D). Mature
vaccinia viruses, about 200 nm in short diameter and 400 nm in
long diameter, were observed both inside the cells (not shown) and
outside of the apical surface (Fig. 3D). No vaccinia viruses were
seen outside the basolateral surface.
The kinetics of p24 and virus distribution post-infection are
shown in Figures 3E and F. The concentrations of dissociative p24
and p24 in VLP were determined using double antibody sandwich
ELISA. Disassociated p24 was found to be expressed in the cells
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p24 in VLP was evaluated using 1% TritonX-100. Results
suggested that increased levels of cellular and apical p24 were
released from the apical surface as well. Basolateral VLP p24 still
could not be detected. For total p24, about 10 ng/well was found
to be present in the cells, about 1–8 ng/well was present in the
apical medium, and none was detected in the basolateral medium.
Viral titer was determined by plaque assay. The virus was found
to replicate at about 10
6 PFU/well in cells and was released from
the apical surface at about 10
4–10
5PFU/well. This is about 1000
times the level in the basolateral medium. Even when the medium
was changed every 48 hours, the kinetics showed similar trends
(data not shown).
After rVTT-gagpol infection, polarized Caco-2 cell layers
assembled progeny vaccinia viruses, expressed HIV genes, and
released viral products from the apical surface. Whether the
situation would be the same in vivo and what impact this preferential
release might have on specific immune responses remained to be
determined. To this end, we studied the interactions between
rVTT-gagpol and the epithelium in BALB/c mice.
Locations of rVTT-gagpol replication and HIV antigen
expression in nasally immunized mice
To identify the amount and location of HIV antigen, mice were
i.n. immunized with rVTT-gagpol and euthanized 1, 10, 24, 48,
72, or 96 hours later. Then plasma, nasal washes, lung bronchial
washes, and homogenized nose and lung tissue samples were
collected. Levels of virus and p24 in these samples were detected
by plaque assay and ELISA, respectively.
Results showed that after mice were i.n. inoculated, the virus
replicated and p24 was expressed in respiratory system but not in the
b l o o d( F i g s .4 A ,B ,C ,D ,E ,a n dF ) .V i r u s e se n t e r e dt h en o s et i s s u e .
Viral levels decreased to their lowest point (10
2 PFU) at about
10 hours and then increased through the first and second days,
r e a c h i n gap e a ka t7 2h o u r s( a b o u t5 610
6 PFU). At the same time,
viruses were released into the lumen of the nose, where viral levels
reached their lowest point (about 8 PFU) at 24 hours and their highest
p o i n t( a b o u t1 0
3 PFU) at 72 hours (Fig. 4B). p24 expression and
distribution took on similar trends. The largest amount of expression
w a sa c h i e v e d ,a b o u t7 0n gp e rm o u s e ,a t7 2h o u r s( F i g .4 A ) .
Viruses were able to reach the lungs when the volume of i.n.
administration exceeded 10 ul. Then the viruses replicated and
p24 was expressed in the lungs (Figs. 4D and C). The lowest virus
and p24 levels were detected at 24 hours and the highest at
72 hours. Viral titers were found to reach 10
6 PFU, lower than
that in nose tissue. For p24, the amount reached 30 ng. If the
volume of i.n. administration was 8 ul, fewer viruses reached the
lungs and peak viral titer only reached 10
5 PFU per mouse (data
not shown). However, neither virus nor p24 was detected in the
blood (Figs. 4E and F). This shows that infection and expression
were restricted to the respiratory system.
In order to determine the exact location of p24 antigen in the
nose and lungs, we performed immunoperoxidase staining of p24
Figure 2. Humoral immune responses to high doses of rVTT-gagpol after i.n. inoculation. Mice were i.n. inoculated with rVTT-gagpol at
weeks 0 and 4 and euthanized during week 6. Sera, lung washes, and vaginal washes taken during week 6 were collected to ascertain anti-p24 IgG
and IgA by ELISA. There were seven mice in each group. Anti-p24 (A) serum IgG, (B) serum IgA, lung wash IgA, and (C) vaginal wash IgA are displayed
above. Three independent experiments were conducted with similar results. The results of one representative experiment are shown.
doi:10.1371/journal.pone.0024296.g002
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J). At 24 hours, there was a little p24 in the epithelium of nose
(Fig. 4G). At 72 hours, there was more p24 but large amounts
remained in the epithelium and only a small amount was found in
lamina propria (Fig. 4H). In the lungs, little p24 was observed at
24 hours (image not shown). A certain amount of p24 was observed
in the epithelia of the lungs at 72 hours and some was delivered to
the alveolar cells (Fig. 4J). The p24 immunohistochemistry results
were considered representative of viral distribution.
rVTT-gagpol was found capable of infecting the epithelial cells of
the nose and lungs. Progeny virus and p24 were constantly released
into the lumen, though only a little reached the lamina propria.
These results correspond withthose of our in vitro experiments. Viral
infection and expression were detected in the respiratory system but
not in the blood. As far as a vaccine development is concerned, it
was expected that antigen would be delivered primarily into the
whole body but not outside it. The limited efficiency of antigen
delivery was found to be due to polarized distribution in the
epithelium. This also suggests that the polarized release is a barrier
to the induction of an efficient immune response. One approach to
improve the situation would be to find a way to induce unpolarized
release of the virus and HIV antigen.
Effects of colchicine on unpolarized distribution of rVTT
and HIV antigen in vitro and in mice
Polarized budding relies upon the cytoskeleton [26,35]. When
its microtubules are depolymerized, proteins that ordinarily target
the apical surface can end up elsewhere [36]. Colchicine, a drug
that inhibits microtubule polymerization, can cause unpolarized
release of the Junin virus in polarized Vero cells [26]. We used
colchicine to inhibit polarized release as follows: After Caco-2 cells
were allowed to polarize for 14–16 days, colchicine was added
apically 72 hours before rVTT-gagpol infection. This group is
here called the polarized + colchicine group. Another polarized
group was infected with rVTT-gagpol only. The unpolarized
groups consisted of infected, unpolarized cells. Caco-2 cells were
cultured in transwell for 3 days, and rVTT-gagpol was then
inoculated. The data presented in Figure 5 were calculated as the
sum of that detected at 48 hours and 72 hours.
Compared to the polarized-only group, the unpolarized and
polarized + colchicine groups showed relatively unpolarized
distributions of p24 and virus (Fig. 5). In the unpolarized group,
the total amount of virus was significantly higher than in the
polarized group. Progeny viruses were released from both the
apical and basolateral surfaces (Fig. 5B). In the colchicine-treated
group, polarized budding was disturbed. The trend of distribution
was similar to that of the unpolarized group. Compared to the
polarized group, the amount of virus in the cells was higher, the
amount in the basolateral medium was 20 times higher, and the
amount in the apical medium was lower (Fig. 5B). p24 distribution
showed a similar trend. In the colchicine-treated group, TER
decreased in the 3 mm transwell (Fig. 5C) but increased in the
0.4 mm transwell at low concentrations (0.08, 0.4 mg/ml). It
decreased at high concentrations (2 mg/ml) (data not shown). In
both the 3 mm (Figs. 5A, B) and 0.4 mm transwells (data not
Figure 3. Infection, expression, and distribution of rVTT-gagpol in polarized Caco-2 monolayer in vitro. Sixteen days after polarization,
Caco-2 cell monolayers were infected by rVTT-gagpol at MOI 1 from the apical surface. At various times, monolayers were fixed and prepared for
electronic microscopy observation, as shown in images (A), (B), (C), and (D). For infection and distribution kinetics, the p24 content and virus titers of
the samples were determined by ELISA and plaque assay, respectively, as shown in images (E) and (F). In detail: (A) Caco-2 monolayer on filter at
48 hours post infection (scale bar: 2 mm). (B) Immature vaccinia virus (x) at 72 hours post infection (scale bar: 1 mm). (C) HIV VLP ( ) about100 nm
in diameter at 72 hours post infection (scale bar: 0.5 mm). (D) HIV VLP ( ) and mature vaccinia virus ( ) about 200 nm in short diameter and
about 400 nm in long diameter released from apical surface (scale bar: 0.5 mm). (E) p24 distribution. Treated samples were treated with 1% TritonX-
100 before testing to release the internal p24 of VLP. (F) rVTT virus distribution. Kinetics experiments were performed in triplicate, three for each
noted point in time. Each electron microscopy observation was performed twice.
doi:10.1371/journal.pone.0024296.g003
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release. In conclusion, colchicine treatment 72 hours before
rVTT-gagpol infection was found to cause unpolarized release
of virus and p24 in vitro.
Next, the impact of colchicine on antigen distribution was
explored in mice epithelia. Colchicine was i.n. inoculated
72 hours before i.n. administration of rVTT-gagpol. PBS was
used as a substitute for colchicine in the control group. Mice
were euthanized at 1, 10, 24, 48, 72, and 96 hours. Then
plasma, nasal washes, lung bronchial washes, and homogenized
nose and lung tissues were collected. Levels of virus and p24 in
these samples were measured by plaque assay and ELISA,
respectively. The results demonstrated that, relative to the
rVTT-gagpol group, the colchicine-treated group showed
consistently higher p24 expression and infection rates in both
nose and nasal washes (Figs. 6A and B), about 70 times higher at
24 hours and about 5 times higher at 72 hours. In the lung and
lung bronchial washes, both p24 and virus levels were much
higher after 48 hours. After 72 hours, both began to decrease,
reaching their lowest points at 96 hours (Figs. 6C and D). No
virus or p24 was detected in the blood of colchicine-treated or
control mice (data not shown).
Regarding p24 distribution in the nose, immunoperoxidase
staining of p24 antigen showed that, at 24 hours, the colchicine-
treated group expressed p24 in the epithelium at a much higher
rate than the group immunized with rVTT-gagpol alone did. The
level of p24 in the lamina propria of both groups was low (Figs. 6E
and F). At 72 hours, the colchicine-treated group expressed p24 at
much higher levels than the rVTT-gagpol immunization group in
both the epithelia and the lamina propria (Figs. 6G and H).
Figure 5. Comparison of distribution of differently treated cell layers after rVTT-gagpol infection in vitro. Caco-2 cell layers were
infected with rVTT-gagpol 14–16 days after polarization to form the polarized group. A similar group was treated with colchicine (0.08 mg/ml)
apically 72 hours before rVTT-gagpol infection to form the polarized + colchicine group. A 3-day Caco-2 transwell culture was infected with rVTT-
gagpol to form the unpolarized group. The data shown are the sums of the 48-hour and 72-hour values. (A) p24 distribution. (B) Virus distribution. (C)
TER. Apical, cellular, and basolateral samples of the three groups were compared. T-testing was conducted to compare the polarized + colchicine
group and unpolarized group to the polarized group. Statistical significance: (P,0.05) in an unpaired test is indicated by an asterisk. There were two
wells for every group. The experiments were performed twice.
doi:10.1371/journal.pone.0024296.g005
Figure 4. Distribution of p24 antigen and vaccinia virus in mice. Six-week-old female BALB/c mice were inoculated i.n. with 1610
7 PFU of
rVTT-gagpol per mouse. For determination of infection and expression kinetics, nose samples, nasal washes, lung samples, lung bronchial washes,
and plasma were collected at specific times. p24 and virus titer were determined by ELISA and plaque assay, respectively (A, B, C, D, E, and F). For
immunoperoxidase staining of p24 antigen, nose and lung tissues were fixed and prepared into paraffin slides, which were stained with
immunoperoxidase (G, H, I, and J). Rabbit anti-p24 served as the first antibody. In detail, p24 distribution in (A) nose samples and nasal washes, (C)
lung samples and lung bronchial washes, and (E) plasma. Virus distribution in (B) nose samples and nasal washes, (D) lung samples and lung bronchial
washes, and (F) plasma. Nose section (G) 24 hours and (H) 72 hours after i.n. inoculation with rVTT-gagpol. (I) Nose section after PBS i.n. inoculation.
(J) Lung section 72 hours after i.n. inoculation. Magnification, 1006.( x) designates epithelium, ( ) designates lamina propria, ( ) and designates
lumen. These images are typical of those observed. There were five mice in each group. The experiments were performed in triplicate.
doi:10.1371/journal.pone.0024296.g004
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24296To ascertain the toxicity and reversibility of the effects of
colchicine, we measured body weight and observed the condition
of mice every other day after immunization. Body weight
decreased after immunization but was restored about 10 days
later (data not shown). The general condition of mice, as evaluated
through coat smoothness and activity level, corresponded with
changes in body weight.
In conclusion, colchicine treatment was found to depolarize the
release of vaccinia virus and p24 both in vitro and in immunized
mice. In mice, it also increased the level of both. Our next task was
to examine specific immune responses.
Effects of unpolarized release of p24 and rVTT-gagpol in
the nasal epithelium on mucosal and systematic immune
responses
We established a colchicine treatment group to determine the
influence of colchicine treatment on specific immune responses.
Mice were i.n. administered rVTT-gagpol (10
7 PFU) and
colchicine (40 mg) at the same time. During the week 4, the mice
were inoculated with colchicine (4 mg) 24 hours before rVTT-
gagpol inoculation. PBS was used as a substitute for colchicine in
the control group. During week 6, mice were euthanized and
blood and mucosal samples were collected.
In the colchicine group, anti-p24 immune responses were
significantly stronger than in the control group (Fig. 7). The serum
IgG titer was about 5 times that of the controls. The serum IgA
was about 5 times higher. The lung bronchial wash IgA titer was
about 10 times higher. The vaginal wash IgA titer was about 3
times higher. Generally, the antibody titers increased depending
on the location of induction. The mucosal level of IgA increased
and systematic effects on IgA and IgG levels were observed.
Colchicine (20 mg/mouse and 4 mg/mouse) was given to mice
to determine its effects on immune responses. We found that the
influence on antibody response at 20 mg was similar to that at
40 mg, but 4-mg doses had no significant effects on anything but
serum IgA titer, which showed a lower level of increase than that
seen at higher doses (data not shown). The conditions of colchicine
treatment for detection of antigen distribution differed slightly
from those used for evaluation of immune responses. Although we
used the same treatment procedure and noted enlarged corre-
sponding immune responses, the results were not stably repro-
ducible. The results shown in Figure 7, however, were both
reproducible and consistent with the idea that colchicine enhances
immune response. There are many factors that might have
influenced the immune responses at some point between antigen
distribution and immune response.
These data suggest that the unpolarized release of vaccinia virus
and antigens renders p24-specific antibody responses more intense.
Discussion
The purpose of the present study was to evaluate the interactions
between HIV recombinant vaccinia virus (rVTT-gagpol) and the
mucosal epithelium and the relationship between antigen distribu-
tion and specific immune responses. Even high doses of most
vaccinia virus vaccine candidates cannot induce strong mucosal IgA
responses, which are related to protection from viral challenge [29].
Other studies have been performed with doses of rVTT ranging
from 2610
6 to 5610
6 PFU/mouse [29,34,37]. Only low specific
antibody titers were produced [29,34]. Large doses are harder to
prepare and can cause side effects. However, i.n. administration of
recombinant vaccinia virus alongside HN or F was found to protect
mice from challenge by Sendai virus via the respiratory duct [29].
When inoculated via either intranasal or intraoral routes,
recombinant vaccinia virus with S protein from SARS-CoV
induced 20–100 times the level of Nab in serum than that induced
by rMVA [22]. A means to increase the efficiency and to reduce
dose size would be useful to researchers, doctors, and patients
interested in this vaccine.
In vitro experiments in which rVTT immunization was
performed via the mucosa, demonstrated that rVTT-gagpol could
infect polarized Caco-2 epithelial layers and that progeny virus
and expressed p24 were released mainly from the apical surface
(Fig. 3). Vermeer et al. also reported that the vaccinia virus infected
differentiated human airway epithelia and was released mainly
from the apical surface in vitro [38]. Huang et al. reported that SIV
budded basolaterally in polarized Vero C1008 cells [39]. Randall
et al. reported that, when polarized Vero-pFN cells were infected
with VVgag, similar amounts of p24 capsid protein were released
into virus particles at the apical and at the basolateral surface. In
contrast, when cells are infected with both VVgag and VVenv,
94% of p24 and all gpl20 are associated with particles released into
the basolateral medium [40]. These results indicate that the HIV-1
envelope glycoprotein renders virus particles containing the gag
protein to be released from the basolateral surface [40]. However,
after we co-infected polarized Caco-2 cells with rVTT-gagpol and
rVTT-env via the apical surface, no increased associative p24 or
VLP p24 was detected in the basolateral medium. We also infected
polarized Vero C1008 cells with rVTT-gagpol via the apical
surface. The integrity of the cell layers deteriorated 4–12 hours
after infection depending on the MOI (data not shown). Before the
cell layers broke down, p24 and vaccinia virus were mainly
released from the apical surface. After that, more p24 and virus
was present in the basolateral medium than in the apical. In
contrast, Caco-2 cell layers maintained their integrity after
infection: p24 and virus were still released mainly from the apical
surface. The reason for this might be that Caco-2 cells are from
the epithelial cells of the colon, which is mucosal tissue, while Vero
cells are derived from the epithelial cells of kidney. This makes
Caco-2 cells more representative of mucosal epithelia in vivo than
Vero cells.
We verified the interaction in immunized mice. rVTT-gagpol
was able to infect respiratory systems, though no viruses or p24
could be detected in the blood (Fig. 4). When mice were
immunized with rVTT-gagpol via the vagina, the virus and p24
were restricted to the vaginal system and could not be detected in
Figure 6. Comparison of p24 and virus distribution between untreated and colchicine-treated rVTT-gagpol immunization groups in
mice. The colchicine-treated group included 6-week-old female BALB/c mice that were i.n. inoculated with colchicine (20 mg) 72 hours before rVTT-
gagpol immunization (1610
7 PFU). The rVTT-gagpol immunization group was given identical treatment except that PBS was used as a substitute for
colchicine. Infection and expression kinetics in nose samples, nasal washes, lung samples, and lung bronchial washes were evaluated (A, B, C, and D).
Immunoperoxidase staining of p24 antigen in the nose (E, F, G, and H). In detail, p24 distribution in (A) nose samples and nasal washes and (C) lung
samples and lung bronchial washes. Virus distribution in (B) nose samples and nasal washes and (D) lung samples and lung bronchial washes. Nose
sections of the rVTT-gagpol immunization group after (E) 24 hours and (G) 72 hours. Nose sections of the colchicine-treated rVTT-gagpol
immunization group after (F) 24 hours and (H) 72 hours. (x) designates epithelium, ( ) designates lamina propria, and ( ) designates lumen. There
were five mice in each group and the images shown are typical of those observed. Magnification, 1006. Two independent experiments were
conducted with similar results. One set of results is shown.
doi:10.1371/journal.pone.0024296.g006
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Recombinant vaccinia virus has been shown to replicate in the
nose and lungs after i.n. inoculation without any virus detectable
in the blood. However, after i.p. inoculation, some virus was
detected in the blood on days 1–4 [29]. Another study focused on
the activity of luciferase in various mouse tissues after immuniza-
tion with recombinant MVA through intranasal (i.n.), intravaginal
(i.v.), and intrarectal (i.r.) routes. After i.n. immunization,
luciferase activity was detected only in the lungs, NALT, and
lung-draining lymph nodes but not in other tissues. In an i.r.
immunization model, activity was not detected in the rectum,
rectal lymph node, or other tissues. Similarly, after i.v. immuni-
zation, no activity was detected in the ovary or vaginal lymph
node. Activity in the vagina lumen was not tested [41].
In contrast to the vaccinia virus, the vesicular stomatitis virus
(VSV) has been found to be released from the basolateral surface
after MDCK infection in vitro [42]. After VSV type New Jersey
(VSV-NJ) was i.n. inoculated in deer mice, infection of the
olfactory epithelium took place on the day 1 and a great deal more
virus was observed in the lamina propria on the day 4. Of the
juvenile and adult deer mice studied, 49% developed virusemia on
days 1, 2, or 3 [43]. These results imply that VSV infects the
epithelium first and then spreads to the lamina propria and blood.
Unlike VSV, vaccinia viruses are mainly released to the lumen,
and it is difficult for them to enter the blood through the lamina
propria.
Because the polarized release of rVTT-gagpol and p24 antigen
limits antigen delivery and specific immune responses, we used
Figure 7. Comparison of anti-p24 humoral immune responses between untreated and colchicine-treated rVTT-gagpol immunization
groups in mice. The colchicine-treated group consisted of five 6-week-old female BALB/c mice that were given i.n. rVTT-gagpol (10
7PFU) and
colchicine (40 mg) at the same time. During week 4, mice were given colchicine boosters (4 mg) 24 hours before rVTT-gagpol. The mice were
euthanized during week 6. The rVTT-gagpol immunization group was given identical treatment except that PBS was used as a substitute for
colchicine. Serum and mucosal samples were collected to test for the presence of anti-p24 antibody by ELISA. Anti-p24 levels of (A) serum IgG, (B)
serum IgA, bronchial wash IgA, and (C) vaginal wash IgA are displayed. T-testing was conducted between the colchicine-treated group and the rVTT-
gagpol immunization group. Statistical significance (P,0.05 in an unpaired test) is indicated by an asterisk. Two independent experiments were
conducted with similar results. One set of results is shown.
doi:10.1371/journal.pone.0024296.g007
Unpolarized Release Enhances Mucosal Responses
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24296colchicine to increase its effectiveness. We showed that colchicine
acts by disrupting polarized release in vitro (Caco-2 cell layers) and
in immunized mice (Figs. 5 and 6). In vitro, the 3-mm pore in the
transwell membrane was used to make sure that rVTT was
released only from the basolateral surface. The 0.4-mm transwell
pore was able to block basolateral release, showing only 1/10
3 as
many basolaterally released viruses as samples equipped with 3-mm
pores. The release of p24 antigen was not significantly different
(data not shown). This implies that, due to the large size of the
vaccinia virus, it passed through 3-mm transwell pores more easily
than through 0.4-mm pores.
In mice, colchicine treatment increased viral infection and
expression of p24 in the nose, nasal washes, and lamina propria
(Fig. 6) with some damage to the epithelium. This is consistent
with the situation in vitro, in which cell layers turned out some
plaques but maintained the integrity of the epithelial layer
relatively well. One explanation of how colchicine treatment was
able to increase the rates of infection and expression may be this:
Colchicine influenced dissemination between cells during the
second period of infection. During rVTT-gagpol infection of the
epithelial cells, progeny viruses were released from the apical
surface, from which they infected neighboring cells, again via the
apical surface (Fig. 8A). Because transportation relies on
microtubules, depolymerization of those microtubules by colchi-
cinie caused some vesicles to target the basolateral surface (Fig. 8B)
[36]. The basolaterally targeted vesicles fused with the upper two
thirds of the lateral surface, not just the region immediately
beneath the tight junction [36]. In addition, vaccinia virus more
readily infects differentiated human airway epithelia from the
basolateral surface than from the apical surface [38]. In this way,
colchicine treatment rendered infected cells much more likely to
infect other cells.
Our results demonstrated that the unpolarized release of virus
and antigen increased specific antibody responses. Other studies
have described the impact of colchicine on immune responses.
Colchicine can act as an immune suppressor at high doses
(100 mg/ml) and an immune enhancer at low doses (0.5–1 mg/ml)
[44]. It can increase immune responses when co-administered with
antigens, enhancing immune response by about a factor of two
[44]. In this study, the doses were 80 mg/ml in vitro and 4–40 mg/
mouse (1000–10,000 mg/ml). Previous reports indicate that both
would result in immune suppression. We found that colchicine
does not act as an immune enhancer under these conditions. In
addition, immune enhancers can more easily enhance specific
immune responses to protein antigens than to live viral vectors.
This is because live viral vectors activate the natural immune
response on their own. In our research, the unpolarized release of
antigen was clear (Figs. 5 and 6) and the immune effect was more
intense and widespread (Fig. 7). The increase in specific antibody
responses were mainly due to the unpolarized release and not to
the slightly nonspecific enhancement of immune responses.
In this study, anti-p24 gag antibodies served as a representatives
of the mucosal humoral response. Although they cannot display
traditional neutralization, they are very important to HIV
vaccines. First, p24-specific IgA neutralizes HIV in cells
intracellularly. This was proven in measles by one member of
our team (unpublished data). She found that viral replication could
be inhibited by binding of the internal protein M of measles by
specific IgA in epithelial cells. This phenomenon was named
intracellular neutralizing. Second, the p24 gag genes are relatively
conservative, so their specific IgA is able to target more than one
subtype of HIV. That of env cannot because its genes mutate
readily.
This study explored the interactions between rVTT-gagpol and
mucosal epithelial cell layers and their impact on antigen delivery
and specific immune responses. Results demonstrate that rVTT-
gagpol can infect epithelial cells to express p24 and that progeny
virus and p24 are mainly released from the apical surface and both
in vitro and in mice. The characteristic polarized distribution
restricts the delivery of antigen and thus specific immune
responses. To improve upon this, colchicine was use to depolarize
distribution. This facilitated antigen expression, delivery, and
specific immune responses. It has been reported before that
polarized release of virus can restrict infection [45], but no
research has yet been performed on the relationship between
polarized release, antigen delivery, and specific immune responses.
These results provide an explanation for the low efficiency of
rVTT-gagpol-induced mucosal immunity and supply some
guidance for vaccine design with an eye toward increasing
immune responses and decreasing dose. First, researchers may
Figure 8. rVTT-gagpol released from (A) the apical surface and (B) the basolateral surface (referenced and modified from [35]).
doi:10.1371/journal.pone.0024296.g008
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viral and antigen distribution and in the epithelium and lamina
propria. Second, they may develop recombinant vaccinia viruses
using genes that target antigen budding from the basolateral
surface, such as the M protein gene of VSV [46,47]. Third, they
may select viruses that are preferentially released from the
basolateral surface, such as VSV, for use as vaccine vectors.
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